Granted Patent B2

US 12,544,415 · App. 18/147,627 · Granted Feb 10, 2026

Inventors: Philippe Slos (Ingwiller, FR); Julie Hortelano (Illkirch, FR); Karola Rittner (Strasbourg, FR); Xavier Preville (Saint Louis, FR)

Assignee: Transgene

A61K35/768A61K38/1709A61K38/2013A61K39/00A61K39/0011A61K39/00114A61K39/12A61K39/39558A61P35/00C07K16/30C12N7/00A61K2039/505A61K2039/5256A61K2039/545A61K2039/55533C07K2317/73C07K2317/76C12N2710/24143C12N2710/24171

Abstract

Claims (27)

1 . A method for treating a proliferative or an infectious disease comprising administering to a subject in need thereof an effective amount of a combination product comprising (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s);

wherein said therapeutic vaccine comprises a modified vaccinia virus Ankara (MVA) encoding membrane anchored Human papilloma Viruses 16 (HPV-16) non-oncogenic E6 and E7 antigens and encoding interleukin 2 (IL-2);

wherein said one or more immune checkpoint modulator(s) comprise(s) a modulator capable of antagonizing at least partially programmed cell death protein 1 (PD-1) pathway; and

wherein said administering of said therapeutic vaccine starts before said administering of said one or more immune checkpoint modulator(s) and

wherein said therapeutic vaccine is administered a first time in a first administration of said therapeutic vaccine separated by a period of time from a first administration of said one or more immune checkpoint modulator(s), and the period of time between the first administration of said therapeutic vaccine and the first administration of said one or more immune checkpoint modulator(s) is one day to eight week(s).

2 . The method of claim 1 , wherein said one or more immune checkpoint modulator(s) comprise(s) a modulator capable of antagonizing at least partially programmed death ligand 1 (PD-L1) or PD-1.

3 . The method of claim 2 , wherein said one or more immune checkpoint modulator(s) comprise(s) a modulator capable of antagonizing at least partially PD-L1.

4 . The method of claim 1 , wherein at least one of said one or more immune checkpoint modulator(s) is an antibody that recognizes human PD-L1.

5 . The method of claim 4 , wherein at least one of said one or more immune checkpoint modulator(s) is a human or humanized monoclonal antibody that specifically binds to PD-L1.

6 . The method according to claim 1 , wherein said proliferative disease is a cancer and wherein said infectious disease results from infection with a virus selected from the group consisting of herpes virus, papillomavirus, poxvirus, retrovirus, HCV, HBV and influenza virus.

7 . The method according to claim 6 , wherein said cancer is selected from the group consisting of renal cancer, prostate cancer, breast cancer, colorectal cancer, lung cancer, liver cancer, gastric cancer, bile duct carcinoma, endometrial cancer, pancreatic cancer and ovarian cancer.

8 . The method according to claim 7 , wherein said cancer is a non-small cell lung cancer (NSCL).

9 . The method according to claim 6 , wherein said cancer is selected from the group consisting of carcinoma, lymphoma, blastoma, sarcoma, leukemia, bone cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, gastric cancer, colorectal cancer, esophageal cancer, oro-pharyngeal cancer, laryngeal cancer, salivary gland carcinoma, thyroid cancer, lung cancer, non-small cell lung cancer, cancer of the head or neck, skin cancer, squamous cell cancer, melanoma, uterine cancer, cervical cancer, endometrial carcinoma, vulvar cancer, ovarian cancer, breast cancer, metastatic breast cancer, prostate cancer, cancer of the endocrine system, sarcoma of soft tissue, bladder cancer, kidney cancer, glioblastoma, cancer of the central nervous system, renal cancer, clear cell carcinoma, hormone refractory prostate adenocarcinoma, hepatocarcinoma, and bile duct carcinoma.

10 . The method according to claim 1 which is carried out in association with one or more conventional therapeutic modalities.

11 . The method according to claim 1 , wherein said therapeutic vaccine and said one or more immune checkpoint modulator(s) are formulated for from 4 to 15 administrations of 10 7 to 10 9 pfu of said MVA at approximately 1 to 3 week intervals interspersed with 2 to 6 administrations of 3 to 10 mg/kg of said one or more immune checkpoint modulator(s) every 2 or 3 weeks.

12 . The method of claim 1 , wherein the period of time between the first administration of said therapeutic vaccine and the first administration of said one or more immune check point modulator(s) is one week to eight week(s).

13 . The method of claim 1 , wherein said administering of a therapeutic vaccine occurs more than once separated by a time interval between each said administering of a therapeutic vaccine that is from 2 days to 8 weeks; and said administering of immune check point modulator(s) occurs more than once separated by a time interval between each administration of immune check point modulator(s) that is from 2 days to 8 weeks.

14 . The method of claim 1 , wherein administration of said combination product results in at least one of:

i. a prolonged survival;

ii. a reduced mortality;

iii. a reduction of a tumor size;

iv. eliciting and/or stimulating and/or redirecting an immune response;

v. eliciting and/or stimulating and/or redirecting an immune response specific to said antigens;

vi. eliciting and/or stimulating and/or redirecting a CD4+ and/or CD8+ T cell response;

vii. an increased IFN-gamma secretion; and

viii. any combination of i. to vii;

in the treated subject.

Assignments (1)

Priority Claims (2)

Continuity (2)

References Cited (127)